{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-030661","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-10-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.140322+00:00","generated_at":"2026-05-30T20:43:47.305114+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Allarity Therapeutics appoints Graff President, Iglesias CMO, Høiland Advisor to advance stenoparib","bullets":["Jeremy Graff, Ph.D., named President & CDO; base salary $475K, RSUs $250K, signing bonus $75K.","Jose Iglesias, M.D., appointed Consultant CMO; led Phase III Abraxane development at Celgene.","Jesper Høiland, former President of Novo Nordisk U.S., joins as Strategic Advisor for commercial strategy.","Appointments target accelerating stenoparib, a dual PARP/Tankyrase inhibitor, for advanced ovarian cancer.","Graff previously consulted for Allarity since Dec 2023; brings 25+ years pharma experience including 17 at Eli Lilly."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-030661","json":"https://secwatch.observer/filing/0001437749-24-030661.json","markdown":"https://secwatch.observer/filing/0001437749-24-030661.md","text":"https://secwatch.observer/filing/0001437749-24-030661.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000143774924030661/0001437749-24-030661-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000143774924030661/allr20241002_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T20:43:47.305114+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0f6f101e17","claim":"Jeremy R. Graff was appointed as President and Chief Development Officer at Allarity Therapeutics, Inc..","evidence_excerpt":"On October 3, 2024, Allarity Therapeutics, Inc. (the “Company”) announced the appointment of Jeremy R. Graff, as the President and Chief Development Officer of the Company effective as of September 30, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000143774924030661/0001437749-24-030661-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Development Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}